Clinical Trials | May 20, 2022
Motilal Oswal Private Equity (MOPE) invests in Pathkind Diagnostics
A primary investment of Rs 194.4 crore has been made
A primary investment of Rs 194.4 crore has been made
Key senior hire will partner with Allison Ceraso, President and CCO, bolstering agency leadership amongst continued network momentum
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
Pharmapack Europe recognizes excellence and innovation from exhibitors across connected devices, sustainability, supply chain logistics, route of administration, and packaging innovation, as well from the wider industry for patient-centric design and eco-design
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
This cost-effective tool will be of immense benefit to other high burden countries as well.
Subscribe To Our Newsletter & Stay Updated
